> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Corcept’s Relacorilant Shows Promise in Ovarian Cancer
- URL: https://www.fdaweb.com/corcepts-relacorilant-shows-promise-in-ovarian-cancer/
- Published: 2025-03-31T12:00:00.000Z
- Updated: 2026-09-14T14:56:35.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158922

Corcept Therapeutics is announcing promising results from its pivotal Phase 3 ROSELLA trial, demonstrating that relacorilant in combination with nab-paclitaxel significantly improves progression-free survival (PFS) in patients with platinum-resistant ovarian cancer. In meeting the trial’s primary endpoint, relacorilant was shown to reduce the risk of disease progression by 30% compared to nab-paclitaxel alone, the company says, adding that patients receiving the combination therapy had a median PFS of 6.5 months, compared to 5.5 months for those on chemotherapy alone, it adds.

“The improvement in survival without added safety burden brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer,” Corcept says. The company says it will submit an NDA in the third quarter.